Clinical TrialJun 10, 2026, 09:21 AM

Optimi Health Exports Psilocybin to UK for Phase 2 Clinical Trial

AI Summary

Optimi Health Corp. announced the completion of its first export of naturally derived psilocybin to the United Kingdom. This shipment, comprising psilocybin biomass and 5mg psilocybin capsules, is intended to support a planned Phase 2 clinical trial in the UK. The company secured necessary export authorization from Health Canada and import authorization from the UK Home Office, manufacturing the product at its GMP facility in Canada.

Key Highlights

Optimi Health completed its first export of naturally derived psilocybin to the United Kingdom.
The shipment includes psilocybin biomass and 5mg psilocybin capsules.
The product is for a planned Phase 2 clinical trial in the UK.
The 5mg capsules use the same formulation prescribed to patients in Australia.
Export was authorized by Health Canada and import by the UK Home Office.
Product manufactured at Optimi's GMP facility in Princeton, British Columbia.

View SEC Filing

OPTH

Pharmaceutical Preparations

Optimi Health Corp.

Price Impact